Literature DB >> 2838959

Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide.

A G Dalgleish1, T C Chanh, R C Kennedy, P Kanda, P R Clapham, R A Weiss.   

Abstract

Three IgM monoclonal antibodies raised against synthetic peptide analogs of a hydrophilic region of the gp41 transmembrane env protein of HIV-1 neutralize different HIV-1 isolates but not HIV-2 isolates, as determined by HIV titration and by syncytial inhibition assays. VSV (HIV-1) pseudotypes, however, were not neutralized, indicating that gp41 was not accessible to these antibodies on the pseudotype particles. The antibodies affect early steps in adsorption and penetration of HIV-1.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2838959     DOI： 10.1016/0042-6822(88)90674-5

Source DB:  PubMed          Journal:  Virology        ISSN： 0042-6822            Impact factor:   3.616


  36 in total

1.  Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein.

Authors:  Thomas S Postler; José M Martinez-Navio; Eloísa Yuste; Ronald C Desrosiers
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

Review 2.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

3.  Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro.

Authors:  W E Robinson; M K Gorny; J Y Xu; W M Mitchell; S Zolla-Pazner
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

Review 4.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

5.  Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.

Authors:  J A Kovacs; M B Vasudevachari; M Easter; R T Davey; J Falloon; M A Polis; J A Metcalf; N Salzman; M Baseler; G E Smith
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

6.  A neutralizing monoclonal antibody previously mapped exclusively on human immunodeficiency virus type 1 gp41 recognizes an epitope in p17 sharing the core sequence IEEE.

Authors:  E Buratti; S G Tisminetzky; P D'Agaro; F E Baralle
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

7.  Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.

Authors:  S H Pincus; K G Messer; D H Schwartz; G K Lewis; B S Graham; W A Blattner; G Fisher
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

8.  Mapping of B-neutralizing and T-helper cell epitopes on the bovine leukemia virus external glycoprotein gp51.

Authors:  I Callebaut; V Vonèche; A Mager; O Fumière; V Krchnak; M Merza; J Zavada; M Mammerickx; A Burny; D Portetelle
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

9.  Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation.

Authors:  A C Andeweg; P Leeflang; A D Osterhaus; M L Bosch
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

10.  Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex.

Authors:  C Wild; J W Dubay; T Greenwell; T Baird; T G Oas; C McDanal; E Hunter; T Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.